drugset

drugset / Trial / NCT00174343

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

NCT00174343 ↗

Phase 2 Completed 46 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)

Timeline

Start: 2001-11
Primary completion: —
Completion: 2006-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Exemestane	Small molecule	—	—

Indications